Genda Biotechnology (Jinhua) Co., Ltd. was established by scientists from Harvard University, Zhejiang University, and the Chinese Academy of Sciences to provide integrated primary-cell solutions. In collaboration with the ZJU-Jinhua Institute, we developed a peptide-based, non-viral, non-lipid nucleic-acid delivery platform for primary cells. The product line includes research-grade transfection reagents and GMP-compliant reagents, supporting the development of advanced cell-therapy products.We warmly welcome partners worldwide to join us in shaping the future of cell therapy.
